Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue? - Nasdaq
4 days ago • Google News
Xenon Pharmaceuticals Inc (XENE)
US$ 30.490.1%
Price Chart
Key Statistics
Market Cap
$ 2.51B
P/E Ratio
0.00
Revenue (TTM)
$ 7.5M
Volume
1.86M
52W High
$ 46.00
52W Low
$ 26.74
Dividend Yield
0.00%
Beta
1.10
Technicals
50-Day MA
32.826
200-Day MA
37.8947
52 Week High
46
52 Week Low
26.74
About XENE
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric di.
Employees
316
Headquarters
Burnaby, BC
CEO
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
Latest News
Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday - Yahoo Finance
2025-05-14 • Google News
Cantor Fitzgerald Estimates XENE FY2026 Earnings - MarketBeat
3 days ago • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg